Affiliation:
1. Latvian Institute of Organic Synthesis, Riga, Latvia
2. Institut des Biomolecules Max Mousseron, Universite de Montpellier, France
Abstract
The utilization of bacterial metalloenzymes, especially ones not having mammalian
(human) counterparts, has drawn attention to develop novel antibacterial agents to overcome
drug resistance and especially multidrug resistance. In this review, we focus on the recent
achievements on the development of inhibitors of bacterial enzymes peptide deformylase
(PDF), metallo-β-lactamase (MBL), methionine aminopeptidase (MetAP) and UDP-3-O-acyl-
N-acetylglucosamine deacetylase (LpxC). The state of the art of the design and investigation
of inhibitors of bacterial metalloenzymes is presented, and challenges are outlined and discussed.
Funder
State Education Development Agency of Latvian Ministry of Education and Science
French Ministry of Foreign Affairs
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Reference138 articles.
1. Available at:World Health Organization: Infectious diseases. Available at: http://www.who.int/topics/infec-tious_diseases/en/ [Accessed November 2017].
2. AMR Review: Tackling drug-resistant infections globally: final report and recommendations (review on antimicrobial resistance 2016. Available at: https://amr-review.org/ [Accessed November 2017].
3. Brown E.D.; Wright G.D.; Nature 2016,529(7586),336-343
4. Kealey C.; Creaven C.A.; Murphy C.D.; Brady C.B.; Biotechnol Lett 2017,39(6),805-817
5. Brown E.D.; Wright G.D.; Chem Rev 2005,105(2),759-774
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献